Scott Rocklage And Kerrisdale Capital Fully Support The Mission Of Expansion Therapeutics

Scott Rocklage is a managing partner at 5AM Ventures, and his company as well as himself are taking a leading role in helping to raise money for Expansion Therapeutics. Sanofi Ventures, Kleiner Perkins, RA Capital Management, Novartis Venture Fund, and Alexandria Venture Investments all took part in the effort by investing in Expansion Therapeutics. The purpose for the Series A fundraising is to further the company’s fight against genetic disorders and especially the genetic disorder known as myotonic dystrophy type I or DM1. This disorder is the main cause for muscular dystrophy, and Expansion Therapeutics has been able to raise over $55 million for its cause, as of yet.


Scott Rocklage has been working in the healthcare industry for most of his life, and he knows how DM1 can have an affect on families. He is also fully aware that modern medicine, at this time, has no answer for DM1 and that the problem lies with the toxic amount of RNA molecules that can be produced inside the cells of some individuals. The problem with the disease is that it can get even worse for each generation that it is handed down to, but it is good that there are companies like Expansion Therapeutics who are looking to create medicines that can deal with RNA diseases like this one.


Scott Rocklage put out a press release indicating that Dr. Mathew D. Disney is the head of scientific research for the Expansion Therapeutics team. Dr. Disney has commented on the fact that he does not plan on giving up until RNA medications have been created that can combat RNA diseases and that he has been more than happy to be a part of the team that has been working for over a decade on the issue. He believes that small molecule medications are the solution and that these kinds of medications are close to being produced.


Scott Rocklage has been working in the healthcare management sector for more than three decades, and he became a Managing Partner with 5AM Ventures in 2004. He studied at the University of California, Berkeley where he received his Bachelor’s of Science Degree in Chemistry, and he continued his education at the Massachusetts Institute of Technology where he earned his Ph.D. in Chemistry. He has worked in a wide variety of leadership positions over the course of his career and was the main reason why Cubicin, Omniscan, and Teslascan were able to get FDA approved.


To learn more, visit

Leave a Reply

Your email address will not be published. Required fields are marked *